ArticleBMC ophthalmology2010
Non-viral siRNA delivery into the mouse retina in vivo.
Article in BMC ophthalmology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Cost-effective strategies to knock down genes of interest in the retinas of adult zebrafish.Frontiers in cellular neuroscience · 2023Article
- The Long Non-Coding RNA HOTAIR Is a Critical Epigenetic Mediator of Angiogenesis in Diabetic Retinopathy.Investigative ophthalmology & visual science · 2021Article
- Efficient Ocular Delivery of VCP siRNA via Reverse Magnetofection in RHO P23H Rodent Retina Explants.Pharmaceutics · 2021Article
- Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art.Frontiers in medicine · 2021Review
- Gene Therapy in Retinal Dystrophies.International journal of molecular sciences · 2019Review
- Activator of G-protein signaling 8 is involved in VEGF-induced choroidal neovascularization.Scientific reports · 2019Article
- Mast cell hyperactivity underpins the development of oxygen-induced retinopathy.The Journal of clinical investigation · 2017Article
- High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy.Cardiovascular diabetology · 2016Article
- Vector platforms for gene therapy of inherited retinopathies.Progress in retinal and eye research · 2014Review
- miR-195 regulates SIRT1-mediated changes in diabetic retinopathy.Diabetologia · 2014Article
- Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes.International journal of molecular sciences · 2014Article
- RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration.PloS one · 2014Article
- Impact of physiochemical properties on pharmacokinetics of protein therapeutics.European journal of drug metabolism and pharmacokinetics · 2013Review
- Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.British journal of pharmacology · 2013Review
- Excitotoxicity upregulates SARM1 protein expression and promotes Wallerian-like degeneration of retinal ganglion cells and their axons.Investigative ophthalmology & visual science · 2013Article
- An influenza virus-inspired polymer system for the timed release of siRNA.Nature communications · 2013Article
- Ameloblastin in Hertwig's epithelial root sheath regulates tooth root formation and development.PloS one · 2013Article
- Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers.Journal of biological engineering · 2012Article
- Progress toward in vivo use of siRNAs-II.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGene silencing in the retina using RNA interference could open broad possibilities for functional studies of genes in vivo and for therapeutic interventions in eye disorders. Therefore, there is a considerable demand for protocols to deliver siRNA into the vertebrate retina. In this work we explored a possibility to deliver synthetic 21 bp siRNA into the mouse retina after intravitreal application using a non-viral carrier.
methodsFluorescently labelled synthetic 21 bp siRNA duplex was combined with Transit-TKO transfection reagent and injected intravitreally into adult mice eyes. Eyes cryostat sections and whole mount retinas were prepared 24-48 h post-injection, stained with either Hoechst 33342 (cell nuclei) or immunostained with anti-GFAP antibody (astroglia cells marker). Distribution of fluorescent siRNA signal in the retina was investigated.
resultsSingle intravitreal injection of as little as 5 ng of siRNA combined with Transit-TKO transfection reagent by a modified protocol provided robust and non-toxic delivery of the siRNA into the retina. However, siRNA accumulation was predominantly confined to ganglion cells layer as analysed 24 h post-injection. Furthermore, siRNA containing particles were localized along GFAP cytoskeleton of retinal astroglial cells hinting on intracellular localization of the siRNA
conclusionsIn this work we demonstrated that siRNA can be efficiently delivered into the vertebrate retina in vivo with low-toxicity using a non-viral carrier, specifically Transit-TKO transfection reagent. However, the capacity of siRNA delivered by our protocol to induce gene silencing in the retina has to be further evaluated. Our report could raise a closer look on Transit-TKO transfection reagent as a promising siRNA carrier in vivo and be of interest for the researchers and companies who work on development of ocular RNAi techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.